You've used all available free searches this month | for more free features.
Clincosm LogoSign in Get a demo

Advanced thyroid cancer

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Thyroid Cancer Trial in Worldwide (Irofulven + capecitabine)

Completed
  • Thyroid Cancer
  • Irofulven + capecitabine
  • Aurora, Colorado
  • +9 more
Jun 11, 2021

Anaplastic Thyroid Cancer, ATC Trial in Shanghai (HLX208)

Recruiting
  • Anaplastic Thyroid Cancer
  • ATC
  • Shanghai, China
    Fudan University Affiliated Oncology Hospital
Dec 30, 2021

DTC - Differentiated Thyroid Cancer Trial in Beijing (Anlotinib HCl)

Recruiting
  • DTC - Differentiated Thyroid Cancer
  • Anlotinib hydrochloride
  • Beijing, China
    Peking Union Medical College Hospital
Jan 18, 2022

Solid Tumor, Medullary Thyroid Cancer Trial in China (Selpercatinib)

Active, not recruiting
Has Results
  • Solid Tumor
  • Medullary Thyroid Cancer
  • Guangzhou, Guangdong, China
  • +12 more
May 9, 2022

Cancer, Solid Tumor, Melanoma Trial (KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose

Not yet recruiting
  • Cancer
  • +16 more
  • KVA12123 - Dose Escalation
  • +3 more
  • (no location specified)
Feb 2, 2023

Medullary Thyroid Cancer Trial (Ponatinib)

Withdrawn
  • Medullary Thyroid Cancer
  • (no location specified)
Oct 6, 2021

Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer Trial in United States (TH1902)

Recruiting
  • Solid Tumor
  • +8 more
  • Los Angeles, California
  • +5 more
Jun 27, 2022

Solid Tumor, Adult, Advanced Solid Tumor, Head Neck Cancer Trial in Irving, San Antonio, West Valley City (SNS-101 (anti-VISTA),

Recruiting
  • Solid Tumor, Adult
  • +19 more
  • Irving, Texas
  • +2 more
May 24, 2023

Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma Trial in Shanghai (individualized mRNA

Not yet recruiting
  • Adrenal Cortical Carcinoma
  • +3 more
  • individualized mRNA neoantigen vaccine (mRNA-0523-L001)
  • Shanghai, Shanghai, China
    Ruijin hospital, Shanghai Jiao-Tong University School of Medicin
Nov 19, 2023

Cancer, BRAF V600 Mutation, Melanoma Trial (XP-102, Trametinib)

Not yet recruiting
  • Cancer
  • +5 more
  • (no location specified)
Aug 18, 2022

Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma Trial in

Recruiting
  • Advanced Differentiated Thyroid Gland Carcinoma
  • +102 more
  • Cabozantinib S-malate
  • Nivolumab
  • Chicago, Illinois
  • +2 more
Apr 5, 2022

Advanced Cancer, Anal Carcinoma, Anal Cancer Trial in Worldwide (pembrolizumab)

Recruiting
  • Advanced Cancer
  • +24 more
  • pembrolizumab
  • Los Angeles, California
  • +21 more
Jan 18, 2023

Thyroid Cancer Trial in Beijing (Anlotinib HCl, Sodium Iodide I 131, Penpulimab)

Recruiting
  • Thyroid Cancer
  • Anlotinib hydrochloride
  • +2 more
  • Beijing, China
    Peking Union Medical College Hospital
Jan 18, 2022

Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer Trial in Spain

Recruiting
  • Metastatic Thyroid Papillary Carcinoma
  • +2 more
  • L'Hospitalet de Llobregat, Barcelona, Spain
  • +14 more
Feb 18, 2022

Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer Trial in Israel, United States (CM-24 and Nivolumab - Dose

Recruiting
  • Solid Tumor
  • +6 more
  • CM-24 and Nivolumab - Dose Escalation
  • +4 more
  • Scottsdale, Arizona
  • +10 more
Jan 17, 2023

Thyroid Cancer, Thyroid Cancer, Medullary, Differentiated Thyroid Cancer Trial in Tampa (Lenvatinib, Sorafenib, Cabozantinib)

Terminated
Has Results
  • Thyroid Cancer
  • +5 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jul 12, 2021

Melanoma, Glioma, Thyroid Cancer Trial (PF-07799544, PF-07284890, PF-07799933)

Not yet recruiting
  • Melanoma
  • +6 more
  • (no location specified)
Sep 9, 2022

Cancer, Solid Tumor, Solid Carcinoma Trial in Houston (AMXT1501, DFMO)

Recruiting
  • Cancer
  • +18 more
  • Houston, Texas
    MD Anderson Cancer Center
Aug 12, 2022

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer

Recruiting
  • Thyroid Cancer
  • NTRK fusion assessment
  • Roma, Italy
    Regina Elena National Cancer Institute
Mar 31, 2023

Advanced Solid Tumor Trial in United Kingdom, United States (CDK-002)

Active, not recruiting
  • Advanced Solid Tumor
  • CDK-002
  • Scottsdale, Arizona
  • +7 more
Sep 27, 2022

NSCLC, Medullary Thyroid Cancer, Solid Tumor Trial in Shanghai, Tianjin (SY-5007)

Recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Shanghai, Shanghai, China
  • +1 more
Mar 17, 2022

Differentiated Thyroid Cancer Trial in Worldwide (Dabrafenib, Trametinib, Trametinib )

Recruiting
  • Differentiated Thyroid Cancer
  • Caba, Buenos Aires, Argentina
  • +41 more
Nov 25, 2022

Differentiated Thyroid Cancer Trial in Nanjing, Peking (Apatinib Oral Tablet, Placebo Oral Tablet)

Active, not recruiting
  • Differentiated Thyroid Cancer
  • Apatinib Oral Tablet
  • Placebo Oral Tablet
  • Nanjing, Jiangsu, China
  • +1 more
Aug 9, 2021

s and Clinical Variables on Thyroid Cancer

Recruiting
  • Thyroid Cancer
    • Milan, Italy
      Istituto Auxologico Italiano, IRCCS
    Mar 1, 2023